Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated:  3/16/2017
Clinical Research Facility
mi
from
Jacksonville, FL
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated: 3/16/2017
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated:  3/16/2017
Clinical Research Facility
mi
from
Portland, ME
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated: 3/16/2017
Clinical Research Facility
mi
from
Portland, ME
Click here to add this to my saved trials
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated:  3/16/2017
Clinical Research Facility
mi
from
St. Louis, MO
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated: 3/16/2017
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated:  3/16/2017
Clinical Research Facility
mi
from
Lansdale, PA
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated: 3/16/2017
Clinical Research Facility
mi
from
Lansdale, PA
Click here to add this to my saved trials
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated:  3/16/2017
Merck Sharp & Dohme (Argentina) Inc.
mi
from
Buenos Aires,
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated: 3/16/2017
Merck Sharp & Dohme (Argentina) Inc.
mi
from
Buenos Aires,
Click here to add this to my saved trials
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated:  3/16/2017
Research Site
mi
from
Sweetwater, FL
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated: 3/16/2017
Research Site
mi
from
Sweetwater, FL
Click here to add this to my saved trials
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated:  3/16/2017
Clinical Research Facility
mi
from
Monroe, LA
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated: 3/16/2017
Clinical Research Facility
mi
from
Monroe, LA
Click here to add this to my saved trials
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated:  3/16/2017
Clinical Research Facility
mi
from
Centerville, OH
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated: 3/16/2017
Clinical Research Facility
mi
from
Centerville, OH
Click here to add this to my saved trials
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated:  3/16/2017
Clinical Research Facility
mi
from
Franklin, TN
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated: 3/16/2017
Clinical Research Facility
mi
from
Franklin, TN
Click here to add this to my saved trials
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated:  3/16/2017
Clinical Research Facility
mi
from
Nashville, TN
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated: 3/16/2017
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated:  3/16/2017
Clinical Research Facility
mi
from
Smyrna, TN
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated: 3/16/2017
Clinical Research Facility
mi
from
Smyrna, TN
Click here to add this to my saved trials
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated:  3/16/2017
Clinical Research Facility
mi
from
Covington, KY
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status: Enrolling
Updated: 3/16/2017
Clinical Research Facility
mi
from
Covington, KY
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Birmingham, AL
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Northport, AL
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Northport, AL
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Chandler, AZ
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Chandler, AZ
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Alhambra, CA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Alhambra, CA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Artesia, CA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Artesia, CA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Huntington Beach, CA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Inglewood, CA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Inglewood, CA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Irvine, CA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Irvine, CA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
LaJolla, CA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
LaJolla, CA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Long Beach, CA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Northridge, CA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Northridge, CA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Norwalk, CA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Norwalk, CA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Pasadena, CA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Pasadena, CA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Sacramento, CA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
San Diego, CA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Santa Monica, CA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Tustin, CA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Tustin, CA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Vista, CA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Vista, CA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
West Hills, CA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
West Hills, CA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Denver, CO
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Norwich, CT
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Norwich, CT
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Hollywood, FL
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Hollywood, FL
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Largo, FL
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Largo, FL
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Miami, FL
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Sarasota, FL
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Sarasota, FL
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
St. Cloud, FL
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
St. Cloud, FL
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Atlanta, GA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Duluth, GA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Duluth, GA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Honolulu, HI
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Honolulu, HI
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Springfield, IL
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Springfield, IL
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
West Yarmouth, MA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
West Yarmouth, MA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
St. Louis, MO
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Henderson, NV
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Henderson, NV
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Las Vegas, NV
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Pahrump, NV
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Pahrump, NV
Click here to add this to my saved trials